Details of the Drug Combination

General Information of Drug Combination (ID: DCC9O0C)

Drug Combination Name
Atorvastatin Fenofibrate
Indication
Disease Entry Status REF
Mixed Dyslipidemia Phase 1 [1]
Component Drugs Atorvastatin   DMF28YC Fenofibrate   DMFKXDY
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Atorvastatin
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Approved [2]
Angina pectoris BA40 Approved [2]
Arteriosclerosis BD40 Approved [2]
Cardiovascular disease BA00-BE2Z Approved [3]
Coronary atherosclerosis N.A. Approved [2]
Hypercholesterolaemia 5C80.0 Approved [2]
Hyperlipidemia 5C80.Z Approved [4]
Hyperlipidemia, familial combined, LPL related N.A. Approved [2]
Hypertriglyceridemia 5C80.1 Approved [2]
Inflammation 1A00-CA43.1 Approved [2]
Non-insulin dependent diabetes 5A11 Approved [2]
Psoriasis EA90 Approved [2]
Type-1/2 diabetes 5A10-5A11 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [5]
Stroke 8B20 Investigative [2]
Venous thromboembolism BD72 Investigative [2]
Atorvastatin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [11]
HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway) TTDJB68 N.A. Inhibitor [12]
------------------------------------------------------------------------------------
Atorvastatin Interacts with 7 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [14]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [15]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [16]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [17]
Monocarboxylate transporter 1 (SLC16A1) DT342ZG MOT1_HUMAN Substrate [18]
Monocarboxylate transporter 2 (SLC16A7) DTLT3UG MOT2_HUMAN Substrate [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DTP(s)
Atorvastatin Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [20]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [21]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [22]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [23]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [24]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Metabolism [25]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Atorvastatin Interacts with 47 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Stromelysin-1 (MMP3) OTGBI74Z MMP3_HUMAN Increases ADR [26]
Kinesin-like protein KIF6 (KIF6) OTDH3MR4 KIF6_HUMAN Increases Response To Substance [27]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Increases Activity [28]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Decreases Expression [29]
Sterol 26-hydroxylase, mitochondrial (CYP27A1) OT649C01 CP27A_HUMAN Decreases Expression [29]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [30]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Expression [31]
Solute carrier family 2, facilitated glucose transporter member 2 (SLC2A2) OTBL2W7R GTR2_HUMAN Decreases Expression [31]
Hexokinase-4 (GCK) OTR3Q0NN HXK4_HUMAN Decreases Expression [31]
Prothrombin (F2) OTNFSM49 THRB_HUMAN Decreases Activity [32]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [33]
Interleukin-2 receptor subunit alpha (IL2RA) OT0MWCHG IL2RA_HUMAN Affects Expression [34]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [35]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [36]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Increases Expression [35]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Affects Expression [37]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Increases Phosphorylation [38]
Rho-related GTP-binding protein RhoC (RHOC) OTOLE1FT RHOC_HUMAN Decreases Localization [39]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [40]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [41]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [41]
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) OT2D9DOV TNR1A_HUMAN Decreases Expression [42]
Integrin alpha-X (ITGAX) OTOGIMHE ITAX_HUMAN Decreases Expression [43]
Tumor necrosis factor receptor superfamily member 5 (CD40) OT5YU2XB TNR5_HUMAN Decreases Expression [34]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [40]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [40]
Interleukin-12 subunit alpha (IL12A) OTDQT8GI IL12A_HUMAN Decreases Expression [44]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Expression [45]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [38]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) OTTOMI8J PK3CA_HUMAN Decreases Expression [33]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [40]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [46]
Importin subunit alpha-1 (KPNA2) OTU7FOE6 IMA1_HUMAN Affects Localization [47]
Microsomal triglyceride transfer protein large subunit (MTTP) OTNUVSDT MTP_HUMAN Decreases Expression [48]
Rho-related GTP-binding protein RhoB (RHOB) OTHQFQF7 RHOB_HUMAN Increases Expression [39]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [37]
CD83 antigen (CD83) OT1V4WQF CD83_HUMAN Decreases Expression [34]
Sterol regulatory element-binding protein 2 (SREBF2) OTBXUNPL SRBP2_HUMAN Increases Localization [49]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) OT7TNF0L AAPK1_HUMAN Increases Activity [50]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [51]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Response To Substance [38]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [52]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Transport [53]
Solute carrier organic anion transporter family member 2B1 (SLCO2B1) OTERJ4VQ SO2B1_HUMAN Increases Uptake [54]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) OTNEN8QK SO1B1_HUMAN Decreases Transport [55]
Solute carrier organic anion transporter family member 1B3 (SLCO1B3) OTOM3BUH SO1B3_HUMAN Increases Uptake [54]
Sister chromatid cohesion protein DCC1 (DSCC1) OTPUVLZT DCC1_HUMAN Affects Response To Substance [56]
------------------------------------------------------------------------------------
⏷ Show the Full List of 47 DOT(s)
Indication(s) of Fenofibrate
Disease Entry ICD 11 Status REF
Coronary atherosclerosis N.A. Approved [6]
High cholesterol level 5C80.0 Approved [7]
Hypercholesterolaemia 5C80.0 Approved [6]
Hyperlipidemia 5C80.Z Approved [6]
Hyperlipidemia, familial combined, LPL related N.A. Approved [6]
Hypertriglyceridemia 5C80.1 Approved [6]
Obesity 5B81 Approved [6]
Fenofibrate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Peroxisome proliferator-activated receptor alpha (PPARA) TTJ584C PPARA_HUMAN Agonist [61]
------------------------------------------------------------------------------------
Fenofibrate Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [62]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Metabolism [63]
------------------------------------------------------------------------------------
Fenofibrate Interacts with 168 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [64]
Phosphoenolpyruvate carboxykinase , mitochondrial (PCK2) OTJ8LX4N PCKGM_HUMAN Increases Expression [65]
Acyl-CoA (FADS1) OTUYOYHX FADS1_HUMAN Increases Expression [66]
Aldo-keto reductase family 1 member B10 (AKR1B10) OTOA4HTH AK1BA_HUMAN Decreases Activity [67]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Increases Expression [68]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [69]
Isocitrate dehydrogenase subunit beta, mitochondrial (IDH3B) OTR89YF5 IDH3B_HUMAN Increases Expression [58]
3-ketoacyl-CoA thiolase, peroxisomal (ACAA1) OTVKRET0 THIK_HUMAN Increases Expression [58]
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADM) OTA4P0FC ACADM_HUMAN Increases Expression [58]
Succinate dehydrogenase iron-sulfur subunit, mitochondrial (SDHB) OTRE1M1T SDHB_HUMAN Increases Expression [58]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1) OTJC60Q7 THIL_HUMAN Increases Expression [58]
Enoyl-CoA hydratase, mitochondrial (ECHS1) OTS0593S ECHM_HUMAN Increases Expression [58]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Increases Expression [58]
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADVL) OT50L4XB ACADV_HUMAN Increases Expression [58]
Succinate--CoA ligase subunit alpha, mitochondrial (SUCLG1) OTDCSPXH SUCA_HUMAN Increases Expression [58]
Trifunctional enzyme subunit beta, mitochondrial (HADHB) OT4Y1I62 ECHB_HUMAN Increases Expression [58]
Methylmalonate-semialdehyde/malonate-semialdehyde dehydrogenase , mitochondrial (ALDH6A1) OT8LCZCT MMSA_HUMAN Increases Expression [58]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Decreases Expression [58]
Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) OTM0A0DY ACOX1_HUMAN Increases Expression [58]
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial (HADH) OTJDOL20 HCDH_HUMAN Increases Expression [58]
Long-chain fatty acid transport protein 4 (SLC27A4) OTWT4HAF S27A4_HUMAN Increases Expression [58]
Aconitate hydratase, mitochondrial (ACO2) OTF2UVNV ACON_HUMAN Increases Expression [58]
Tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) OTQ4W7MT TR11B_HUMAN Decreases Expression [59]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Decreases Expression [59]
Krueppel-like factor 11 (KLF11) OTKVQDJD KLF11_HUMAN Increases Expression [59]
Long-chain fatty acid transport protein 2 (SLC27A2) OT7JEG5F S27A2_HUMAN Increases Expression [59]
Transcription intermediary factor 1-alpha (TRIM24) OTA45FTS TIF1A_HUMAN Increases Expression [59]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Decreases Expression [59]
Interleukin-1 receptor-associated kinase-like 2 (IRAK2) OT6Y1QZN IRAK2_HUMAN Increases Expression [59]
Proline dehydrogenase 1, mitochondrial (PRODH) OT7SQ1C7 PROD_HUMAN Decreases Expression [59]
LYR motif-containing protein 1 (LYRM1) OTV3AJDJ LYRM1_HUMAN Increases Expression [59]
Mitochondrial carnitine/acylcarnitine carrier protein (SLC25A20) OT6CLFXB MCAT_HUMAN Increases Expression [59]
Perilipin-1 (PLIN1) OT3OAAZ4 PLIN1_HUMAN Increases Expression [59]
Peroxisomal membrane protein 11A (PEX11A) OT8MJ9CJ PX11A_HUMAN Increases Expression [59]
Tumor necrosis factor receptor superfamily member 21 (TNFRSF21) OT3EDGXO TNR21_HUMAN Increases Expression [59]
2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial (GCAT) OT6WZPWV KBL_HUMAN Decreases Expression [59]
Alcohol dehydrogenase 1C (ADH1C) OTO1DV7F ADH1G_HUMAN Decreases Expression [59]
L-lactate dehydrogenase B chain (LDHB) OT9B1CT3 LDHB_HUMAN Increases Expression [59]
Galactose-1-phosphate uridylyltransferase (GALT) OTCATU66 GALT_HUMAN Increases Expression [59]
All-trans-retinol dehydrogenase ADH4 (ADH4) OTKDKKNG ADH4_HUMAN Decreases Expression [59]
Electron transfer flavoprotein subunit alpha, mitochondrial (ETFA) OTXX61VZ ETFA_HUMAN Increases Expression [59]
Fumarylacetoacetase (FAH) OTGZA1YR FAAA_HUMAN Increases Expression [59]
Arylacetamide deacetylase (AADAC) OT8VACT2 AAAD_HUMAN Increases Expression [59]
Plasma membrane calcium-transporting ATPase 4 (ATP2B4) OTMWFDAC AT2B4_HUMAN Increases Expression [59]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Increases Expression [59]
Glycerol kinase (GK) OTK2YRA0 GLPK_HUMAN Increases Expression [59]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Expression [59]
Phosphoenolpyruvate carboxykinase, cytosolic (PCK1) OTNWEJ5Y PCKGC_HUMAN Increases Expression [59]
Glucose-6-phosphatase catalytic subunit 1 (G6PC1) OTJ6FM9F G6PC1_HUMAN Decreases Expression [59]
Trifunctional enzyme subunit alpha, mitochondrial (HADHA) OTO557N2 ECHA_HUMAN Increases Expression [59]
Flavin-containing monooxygenase 5 (FMO5) OTTILF8T FMO5_HUMAN Decreases Expression [59]
Hydroxymethylglutaryl-CoA synthase, mitochondrial (HMGCS2) OTC3RUN9 HMCS2_HUMAN Increases Expression [59]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Increases Expression [59]
Krueppel-like factor 10 (KLF10) OT4F4UGS KLF10_HUMAN Increases Expression [59]
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) OTTUU92F ENPP2_HUMAN Decreases Expression [59]
Glycine N-methyltransferase (GNMT) OT0O2OQO GNMT_HUMAN Decreases Expression [59]
Monocyte to macrophage differentiation factor (MMD) OTB5I4OC PAQRB_HUMAN Increases Expression [59]
2'-5'-oligoadenylate synthase-like protein (OASL) OTZ05YRP OASL_HUMAN Increases Expression [59]
Myosin light chain kinase, smooth muscle (MYLK) OT78QB4A MYLK_HUMAN Decreases Expression [59]
Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial (ETFDH) OTOSKSFH ETFD_HUMAN Increases Expression [59]
Laminin subunit alpha-4 (LAMA4) OTHI7TA0 LAMA4_HUMAN Increases Expression [59]
kinase isozyme 4, mitochondrial (PDK4) OTCMHMBZ PDK4_HUMAN Increases Expression [59]
Phospholipase A1 member A (PLA1A) OT2IXYNX PLA1A_HUMAN Increases Expression [59]
Protein LBH (LBH) OT87AT1X LBH_HUMAN Increases Expression [59]
NEDD4-binding protein 2-like 1 (N4BP2L1) OTEGV3GO N42L1_HUMAN Increases Expression [59]
Cytochrome P450 4A22 (CYP4A22) OTHO7KC4 CP4AM_HUMAN Increases Expression [59]
Protein FAM222A (FAM222A) OTRD9AUH F222A_HUMAN Increases Expression [59]
PI-PLC X domain-containing protein 3 (PLCXD3) OTJNSWMU PLCX3_HUMAN Decreases Expression [59]
Cyclic AMP-responsive element-binding protein 3-like protein 3 (CREB3L3) OTDMU3GP CR3L3_HUMAN Increases Expression [59]
Lysophospholipid acyltransferase 5 (LPCAT3) OTWI96P4 MBOA5_HUMAN Increases Expression [59]
Solute carrier family 25 member 34 (SLC25A34) OTY1YFLG S2534_HUMAN Increases Expression [59]
Leucine-rich repeat-containing protein 31 (LRRC31) OT7VCU13 LRC31_HUMAN Increases Expression [59]
Lysophosphatidylcholine acyltransferase 2 (LPCAT2) OT6NTBAA PCAT2_HUMAN Increases Expression [59]
Monocarboxylate transporter 13 (SLC16A13) OTAJ5CPB MOT13_HUMAN Increases Expression [59]
Target of Nesh-SH3 (ABI3BP) OTW8DN50 TARSH_HUMAN Decreases Expression [59]
Alpha-protein kinase 2 (ALPK2) OTWZZDQ9 ALPK2_HUMAN Increases Expression [59]
4-hydroxy-2-oxoglutarate aldolase, mitochondrial (HOGA1) OT7XETW4 HOGA1_HUMAN Decreases Expression [59]
Sphingosine-1-phosphate transporter SPNS2 (SPNS2) OTPODAPU SPNS2_HUMAN Increases Expression [59]
Cyclin-dependent kinase 20 (CDK20) OTOLNN68 CDK20_HUMAN Increases Expression [59]
Cytochrome P450 4X1 (CYP4X1) OTMTEUNE CP4X1_HUMAN Increases Expression [59]
Uncharacterized protein FAM241A (FAM241A) OTC12ETA F241A_HUMAN Increases Expression [59]
Sodium-dependent lysophosphatidylcholine symporter 1 (MFSD2A) OTVG1VG0 NLS1_HUMAN Decreases Expression [59]
Pantothenate kinase 1 (PANK1) OT2CZVRT PANK1_HUMAN Increases Expression [59]
Thyroid hormone-inducible hepatic protein (THRSP) OTKYE01L THRSP_HUMAN Decreases Expression [59]
Interferon regulatory factor 7 (IRF7) OTC1A2PQ IRF7_HUMAN Increases Expression [59]
Bcl-2-modifying factor (BMF) OT90NSLI BMF_HUMAN Increases Expression [59]
Membrane-spanning 4-domains subfamily A member 10 (MS4A10) OTH3LAUX M4A10_HUMAN Decreases Expression [59]
Perilipin-2 (PLIN2) OTRXJ9UN PLIN2_HUMAN Increases Expression [59]
C-C motif chemokine 13 (CCL13) OTNX0JD0 CCL13_HUMAN Increases Expression [59]
Ion channel TACAN (TMEM120A) OTBS3YWY TACAN_HUMAN Decreases Expression [59]
Alanine--glyoxylate aminotransferase 2, mitochondrial (AGXT2) OTO6QUTM AGT2_HUMAN Decreases Expression [59]
cAMP-dependent protein kinase inhibitor beta (PKIB) OT7C8GFN IPKB_HUMAN Increases Expression [59]
Potassium channel subfamily K member 13 (KCNK13) OTMOT2KX KCNKD_HUMAN Increases Expression [59]
Serine/threonine-protein kinase Sgk2 (SGK2) OTCTVSHF SGK2_HUMAN Increases Expression [59]
Acetyl-coenzyme A synthetase, cytoplasmic (ACSS2) OTB1FZJU ACSA_HUMAN Decreases Expression [59]
Protein C19orf12 (C19ORF12) OTVSJ1AR CS012_HUMAN Increases Expression [59]
Ethanolamine kinase 2 (ETNK2) OT5S1Z75 EKI2_HUMAN Decreases Expression [59]
SH3 domain-binding glutamic acid-rich-like protein 2 (SH3BGRL2) OTOX4XT7 SH3L2_HUMAN Increases Expression [59]
Podocalyxin (PODXL) OTPNQXF3 PODXL_HUMAN Decreases Expression [60]
Class E basic helix-loop-helix protein 40 (BHLHE40) OTITX14U BHE40_HUMAN Decreases Expression [60]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [60]
Branched-chain-amino-acid aminotransferase, mitochondrial (BCAT2) OT8L6EGI BCAT2_HUMAN Increases Expression [60]
Transcription factor MafG (MAFG) OTBQFUZH MAFG_HUMAN Increases Expression [60]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1) OTEAUJXN TRIA1_HUMAN Decreases Expression [60]
NUAK family SNF1-like kinase 1 (NUAK1) OTLLHJJQ NUAK1_HUMAN Decreases Expression [60]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A) OTYG179K PR15A_HUMAN Increases Expression [60]
Solute carrier organic anion transporter family member 2B1 (SLCO2B1) OTERJ4VQ SO2B1_HUMAN Decreases Expression [60]
Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 (GCNT3) OTQ9ALTR GCNT3_HUMAN Increases Expression [60]
Alpha-enolase (ENO1) OTB1KWJS ENOA_HUMAN Increases Expression [60]
Bifunctional glutamate/proline--tRNA ligase (EPRS1) OTXK0FLB SYEP_HUMAN Increases Expression [60]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Increases Expression [60]
RNA-binding protein RO60 (RO60) OTLGM5A8 RO60_HUMAN Decreases Expression [60]
Histone H1.2 (H1-2) OT0AVI4M H12_HUMAN Decreases Expression [60]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Affects Activity [60]
Transcription factor E3 (TFE3) OTM99ZWH TFE3_HUMAN Increases Expression [60]
B-cell lymphoma 3 protein (BCL3) OT1M5B95 BCL3_HUMAN Decreases Expression [60]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Decreases Expression [60]
ETS domain-containing protein Elk-4 (ELK4) OTVSSEOE ELK4_HUMAN Increases Expression [60]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [60]
Glycine--tRNA ligase (GARS1) OT5B6R9Y GARS_HUMAN Increases Expression [60]
Isoleucine--tRNA ligase, cytoplasmic (IARS1) OT9WXH5N SYIC_HUMAN Increases Expression [60]
Eukaryotic translation initiation factor 1 (EIF1) OTB4GZ0V EIF1_HUMAN Increases Expression [60]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Increases Expression [60]
Branched-chain-amino-acid aminotransferase, cytosolic (BCAT1) OTYHXLWZ BCAT1_HUMAN Decreases Expression [60]
Serine/threonine-protein kinase SIK1 (SIK1) OT6FCHME SIK1_HUMAN Increases Expression [60]
Large neutral amino acids transporter small subunit 1 (SLC7A5) OT2WPVXD LAT1_HUMAN Increases Expression [60]
1,4-alpha-glucan-branching enzyme (GBE1) OTK2N05B GLGB_HUMAN Increases Expression [60]
Ras-related protein Rab-31 (RAB31) OTMLXQZ0 RAB31_HUMAN Decreases Expression [60]
Probable E3 ubiquitin-protein ligase HERC3 (HERC3) OTWMKYD9 HERC3_HUMAN Increases Expression [60]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Decreases Expression [60]
Neuronal regeneration-related protein (NREP) OT2AZPKK NREP_HUMAN Decreases Expression [60]
Dual specificity protein phosphatase 5 (DUSP5) OTH96RA7 DUS5_HUMAN Increases Expression [60]
Glycerol-3-phosphate acyltransferase 3 (GPAT3) OTJUGPK0 GPAT3_HUMAN Increases Expression [60]
Quinone oxidoreductase PIG3 (TP53I3) OTSCM68G QORX_HUMAN Decreases Expression [60]
Probable ATP-dependent RNA helicase DHX37 (DHX37) OTM1A5KP DHX37_HUMAN Increases Expression [60]
SH3 domain and tetratricopeptide repeat-containing protein 1 (SH3TC1) OT0HYZIU S3TC1_HUMAN Increases Expression [60]
Sortilin-related receptor (SORL1) OTQ8FFNS SORL_HUMAN Decreases Expression [60]
KICSTOR complex protein ITFG2 (ITFG2) OT0NLZ8I ITFG2_HUMAN Increases Expression [60]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1) OT2363Z9 T53I1_HUMAN Decreases Expression [60]
Protein FAM89A (FAM89A) OTNASAXT FA89A_HUMAN Increases Expression [60]
Spermatid perinuclear RNA-binding protein (STRBP) OTU7XLZL STRBP_HUMAN Increases Expression [60]
Protein orai-3 (ORAI3) OTUP3OH3 ORAI3_HUMAN Decreases Expression [60]
Ferroptosis suppressor protein 1 (AIFM2) OT57XWXO FSP1_HUMAN Increases Expression [60]
Sulfiredoxin-1 (SRXN1) OTYDBO4L SRXN1_HUMAN Increases Expression [60]
Ankyrin repeat family A protein 2 (ANKRA2) OTLSLV5A ANRA2_HUMAN Increases Expression [60]
Gephyrin (GPHN) OTAKK1SV GEPH_HUMAN Increases Expression [60]
Ectonucleoside triphosphate diphosphohydrolase 7 (ENTPD7) OT3QER33 ENTP7_HUMAN Decreases Expression [60]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Decreases Expression [60]
Leucine--tRNA ligase, cytoplasmic (LARS1) OT4557NF SYLC_HUMAN Increases Expression [60]
Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (ARFGEF2) OTM3CQZT BIG2_HUMAN Increases Expression [60]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Increases Expression [70]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Decreases Expression [71]
Matrilysin (MMP7) OTVT3SEJ MMP7_HUMAN Decreases Expression [71]
Fatty acid-binding protein, adipocyte (FABP4) OT3DKFOU FABP4_HUMAN Increases Expression [72]
Polyunsaturated fatty acid lipoxygenase ALOX12 (ALOX12) OTFL5KR5 LOX12_HUMAN Increases Expression [72]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Affects Localization [71]
Tumor necrosis factor receptor superfamily member 5 (CD40) OT5YU2XB TNR5_HUMAN Decreases Expression [73]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Expression [74]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Decreases Expression [75]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A) OTI862QH CPT1A_HUMAN Increases Expression [76]
5'-AMP-activated protein kinase subunit gamma-1 (PRKAG1) OTW00PRY AAKG1_HUMAN Increases Expression [71]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [73]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [73]
Nuclear receptor subfamily 0 group B member 2 (NR0B2) OT7UVICX NR0B2_HUMAN Increases Expression [77]
Tribbles homolog 3 (TRIB3) OTG5OS7X TRIB3_HUMAN Decreases Expression [78]
Semaphorin-6B (SEMA6B) OT3VVVUO SEM6B_HUMAN Decreases Expression [79]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) OT1OG4QZ AAKB1_HUMAN Increases Phosphorylation [71]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) OT7TNF0L AAPK1_HUMAN Decreases Response To Substance [71]
------------------------------------------------------------------------------------
⏷ Show the Full List of 168 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Diabetes Mellitus DCLQLI4 N. A. Phase 1 [80]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00300469) Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
2 Atorvastatin FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 205945.
5 ClinicalTrials.gov (NCT04380402) Atorvastatin in COVID-19. U.S. National Institutes of Health.
6 Fenofibrate FDA Label
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7186).
8 Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium. 2005 Sep-Dec;12(5-6):233-41.
9 Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis. 2009 Sep;19(7):481-90. doi: 10.1016/j.numecd.2008.10.003. Epub 2009 Jan 26.
10 Simvastatin reduces VCAM-1 expression in human umbilical vein endothelial cells exposed to lipopolysaccharide. Inflamm Res. 2012 May;61(5):485-91. doi: 10.1007/s00011-012-0435-9. Epub 2012 Jan 15.
11 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
12 Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 29. pii: pvaa042.
13 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
14 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
15 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
16 FDA Drug Development and Drug Interactions
17 Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
18 H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
19 Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
22 Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
23 Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
24 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
25 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
26 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
27 [Association of a polymorphic marker Trp719Arg of KIF6 gene with effects of atorvastatin and simvastatin in patients with early ischemic heart disease]. Kardiologiia. 2011;51(9):4-12.
28 Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
29 Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol. 2006 Feb 28;71(5):605-14.
30 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
31 Involvement of pregnane X receptor in the impaired glucose utilization induced by atorvastatin in hepatocytes. Biochem Pharmacol. 2016 Jan 15;100:98-111.
32 Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost. 2006 Nov;4(11):2397-404. doi: 10.1111/j.1538-7836.2006.02165.x. Epub 2006 Aug 14.
33 Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway. Chem Biol Interact. 2018 May 1;287:32-40. doi: 10.1016/j.cbi.2018.04.005. Epub 2018 Apr 6.
34 Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
35 Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem. 2007 Aug 15;101(6):1430-8. doi: 10.1002/jcb.21259.
36 Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels. 2005 Jul;20(4):133-6. doi: 10.1007/s00380-005-0833-9.
37 Atorvastatin induces mitochondrial dysfunction and cell apoptosis in HepG2 cells via inhibition of the Nrf2 pathway. J Appl Toxicol. 2019 Oct;39(10):1394-1404. doi: 10.1002/jat.3825. Epub 2019 Aug 18.
38 Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 2010 Oct 1;70(19):7699-709. doi: 10.1158/0008-5472.CAN-10-1626. Epub 2010 Sep 28.
39 Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer. 2008 May 1;122(9):2115-24. doi: 10.1002/ijc.23315.
40 RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006 Nov;13(11):1845-56. doi: 10.1038/sj.cdd.4401873. Epub 2006 Feb 10.
41 Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc.
42 The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol. 2005 Dec 15;96(12):1699-704. doi: 10.1016/j.amjcard.2005.07.092. Epub 2005 Oct 28.
43 Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin. Rom J Intern Med. 2007;45(2):193-9.
44 Treatment with atorvastatin alters the ratio of interleukin-12/interleukin-10 gene expression [corrected]. Eur J Clin Invest. 2003 Jan;33(1):88-91. doi: 10.1046/j.1365-2362.2003.01105.x.
45 Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study. Am Heart J. 2006 Jan;151(1):139. doi: 10.1016/j.ahj.2005.10.006.
46 Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol. 2004 Apr 7;43(7):1188-94. doi: 10.1016/j.jacc.2003.10.046.
47 Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients. Viruses. 2021 Oct 15;13(10):2084. doi: 10.3390/v13102084.
48 Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
49 Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol. 2001 Dec 1;62(11):1545-55. doi: 10.1016/s0006-2952(01)00790-0.
50 Atorvastatin and pravastatin stimulate nitric oxide and reactive oxygen species generation, affect mitochondrial network architecture and elevate nicotinamide N-methyltransferase level in endothelial cells. J Appl Toxicol. 2021 Jul;41(7):1076-1088. doi: 10.1002/jat.4094. Epub 2020 Oct 19.
51 Atorvastatin mediates increases in intralesional BAX and BAK expression in human end-stage abdominal aortic aneurysms. Can J Physiol Pharmacol. 2009 Nov;87(11):915-22. doi: 10.1139/y09-085.
52 Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis. 2011 Dec;16(12):1268-84.
53 Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res. 2000 Feb;17(2):209-15. doi: 10.1023/a:1007525616017.
54 The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):244-50. doi: 10.1111/bcpt.12031. Epub 2012 Dec 6.
55 Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22.
56 Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis. Toxicol Appl Pharmacol. 2022 Oct 1;452:116169. doi: 10.1016/j.taap.2022.116169. Epub 2022 Aug 1.
57 Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology. 2006 Nov;44(5):1158-70.
58 Linalool is a PPARalpha ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110.
59 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
60 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
61 Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
62 Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
63 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
64 The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. Kardiol Pol. 2005 Jun;62(6):526-30.
65 In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer. 2006 Mar 28;5:13.
66 Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Eur J Pharmacol. 2007 Oct 1;571(2-3):97-105.
67 Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. Eur J Pharmacol. 2008 Apr 28;584(2-3):213-21.
68 Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
69 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
70 On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis. 2009 Aug;205(2):413-9. doi: 10.1016/j.atherosclerosis.2009.01.008. Epub 2009 Jan 19.
71 AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF-B pathway. Environ Toxicol. 2016 Jul;31(7):866-76. doi: 10.1002/tox.22097. Epub 2014 Dec 24.
72 Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003 May;52(5):652-7. doi: 10.1053/meta.2003.50100.
73 Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis. Leukemia. 2010 Aug;24(8):1476-86. doi: 10.1038/leu.2010.117. Epub 2010 Jun 3.
74 Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care. 2006 Feb;29(2):195-201. doi: 10.2337/diacare.29.02.06.dc05-1418.
75 Fenofibrate induced PPAR alpha expression was attenuated by oestrogen receptor alpha overexpression in Hep3B cells. Environ Toxicol. 2018 Feb;33(2):234-247. doi: 10.1002/tox.22511. Epub 2017 Nov 14.
76 Immunoselection and characterization of a human genomic PPAR binding fragment located within POTE genes. Biochimie. 2007 Mar;89(3):329-36. doi: 10.1016/j.biochi.2006.09.017. Epub 2006 Oct 18.
77 Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. Hepatology. 2009 Sep;50(3):880-92. doi: 10.1002/hep.23049.
78 PML-RAR interaction with TRIB3 impedes PPAR/RXR function and triggers dyslipidemia in acute promyelocytic leukemia. Theranostics. 2020 Aug 15;10(22):10326-10340. doi: 10.7150/thno.45924. eCollection 2020.
79 Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells. Int J Oncol. 2006 Apr;28(4):977-84.
80 ClinicalTrials.gov (NCT00491400) Effect of a Fibrate and a Statin on Endothelial Dysfunction